Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

Sanofi (NASDAQ:SNY) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. Sanofi (NASDAQ:SNY) said on ...

Proving her illness created an illusion of wellness for columnist Ahna Crum, but a relapse after nine years showed her she ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...

Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...

Scientists from UCL have used artificial intelligence to discover two new biological sub-types of multiple sclerosis ...

Researchers say the more they find out, the more likely 'we will be able to find treatments that can stop disease progression ...